Monocentric Phase 1 Study With Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Siltuximab (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms SILTUXILAM
- 04 Apr 2023 Status changed from not yet recruiting to recruiting.
- 31 Jan 2023 New trial record